TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may drive more aggressive disease.
To determine clinical outcomes of single and compound TSG alterations across the spectrum of prostate cancer.